Additional file 1 of Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity
Creators: name: Weber, Daniela D.
name: Aminzadeh-Gohari, Sepideh
name: Thapa, Maheshwor
name: Redtenbacher, Anna-Sophia
name: Catalano, Luca
name: Capelôa, Tânia
name: Vazeille, Thibaut
name: Emberger, Michael
name: Felder, Thomas K.
name: Feichtinger, René G.
name: Koelblinger, Peter
name: Dallmann, Guido
name: Sonveaux, Pierre
name: Lang, Roland
name: Kofler, Barbara
Publisher: name: figshare
Year: 2022
Subjects: subject: Biochemistry
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Physiology
subject: Pharmacology
subject: Ecology
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Cancer
subject: Computational Biology

description: Additional file 1: Fig. S1. Expression of OXPHOS and glycolysis markers in melanoma xenografts. A-E Immunohistochemical staining of A OXPHOS complex I (CI), B complex II (CII), C complex IV (CIV), D hexokinase 2 (HK2), and E glucose transporter 1 (GLUT1) in A375, WM47, WM3311, and WM3000 tumors from mice fed a control diet. Individual data points and median; n = 5-6; p values were determined by a Kruskal-Wallis test with Dunn's multiple comparisons test; **p&lt;0.01, ***p&lt;0.001. Images show representative CI, CII, CIV, HK2, and GLUT1 staining in A375-, WM47-, WM3311-, and WM3000-xenografts. Scale bar = 100 μm. Fig. S2. Tumor growth of melanoma xenografts from mice fed a control diet or KDs. A-L Tumor growth curves of A-C A375, D-F WM47, G-I WM3311 and J-L WM3000 melanoma xenografts in single CD-1 nude mice treated with CTRL, LCT or LCT-MCT diet. Fig. S3. Effect of KDs on tumor necrosis in melanoma xenografts. A-D Percentage of necrosis in A A375, B WM47, C WM3311, and D WM3000 tumors from mice treated with CTRL, LCT or LCT-MCT diet scored in haematoxylin and eosin (HE) stained histological sections of xenografts. Individual data point and median; n = 6-12; p values were determined by a Kruskal-Wallis test with Dunn's multiple comparisons test, *p&lt;0.05, **p&lt;0.01. Images show representative HE stained A375-, WM47-, WM3311-, and WM3000-xenografts from mice fed a CTRL, LCT or LCT-MCT diet. Scale bar = 200 μm. Fig. S4. Body weight of melanoma xenograft-bearing mice treated with a control diet or KDs. A-L Body weight curves of A-C A375, D-F WM47, G-I WM3311 and J-L WM3000 melanoma-bearing single CD-1 nude mice treated with CTRL, LCT or LCT-MCT diet. Net body weight is shown as % of the initial body weight. Body weight loss &gt;20% was a termination criterion. Fig. S5. Beta-hydroxybutyrate and acetoacetate have no effect on proliferation of human melanoma cells in vitro. A-D Treatment of human melanoma cell lines A A375, B WM47, C WM3311, and D WM3000 with 2.5, 5, and 10 mM beta-hydroxybutyrate (BHB), lithium-acetoacetate (LiAcAc) and lithium-chloride (LiCl). p values were determines by a one-way ANOVA with Dunnett's multiple comparisons test; n = 8 from 2 independent experiments. Fig. S6. Tumor growth and body weight of B16-M4b-melanoma bearing syngeneic C57BL/6j mice treated with a control diet or KDs. A-C Tumor growth curves of single B16-M4b melanoma allografts treated with A CTRL, B LCT or C LCT-MCT diet. D-F Body weight curves of single B16-M4b-melanoma bearing mice treated with D CTRL, E LCT or F LCT-MCT diet. Net body weight is shown as % of the initial body weight. Body weight loss &gt;20% was a termination criterion.